DiogenX 

DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of diabetic patients around the world.

DiogenX is developing a first-in-class recombinant protein that aims to replicate insulin-producing beta cells in the pancreas of type 1 diabetes patients. This novel approach has the potential to offer a disease-modifying therapy for type 1 diabetes, a chronic and life-threatening condition that affects millions of people worldwide.

https://diogenx.com//

For more information, please contact:

Claus Andersson, PhD

General Partner

Phone: +45 2270 5065